SELLAS Life Sciences Group (SLS) Q3 2026 earnings summary

Executive summary

• REGAL reached its prespecified 80-death threshold on October 28, triggering final analysis; preliminary topline results were expected in November 2026.

• SLS009’s randomized Phase 2 trial in newly diagnosed AML had enrolled 40 of 80 patients by November 5, with enrollment ongoing and preliminary topline data expected in Q4 2026.

• Cash and cash equivalents totaled $134.7 million at September 30, 2026.

Financial highlights

• Q3 2026 operating expenses were $11.3 million and net loss was $10.1 million, versus $7.1 million and $6.8 million in Q3 2025.

• 9M 2026 operating expenses were $31.2 million and net loss was $28.1 million, versus $20.0 million and $19.2 million in 9M 2025; no product sales revenue was generated.

• Q3 R&D expense rose to $7.0 million from $4.2 million; 9M R&D increased to $18.4 million from $11.3 million, mainly reflecting SLS009 trial activity and GPS clinical, regulatory and manufacturing preparation.

• Q3 G&A expense was $4.3 million versus $2.9 million; 9M G&A was $12.8 million versus $8.7 million, including a $1.0 million charge for allocated 3D Medicines arbitration costs.

• Cash and cash equivalents rose to $134.7 million at September 30, 2026, from $71.8 million at December 31, 2025.

Outlook and guidance

• REGAL topline primary-endpoint results were expected in November after database lock, blinded review, statistical analysis and unblinding.

• Preliminary topline results from the newly diagnosed AML SLS009 trial were expected in Q4 2026; enrollment and dosing continued toward 80 patients.

• GPS development and manufacturing preparations for a potential BLA filing were expected to continue following REGAL final analysis, subject to trial results and FDA agreement.

• Cash was expected to fund planned operations for at least 12 months from issuance of the financial statements; R&D expenses were expected to rise as GPS and SLS009 trials advanced.

• SLS009 relapsed/refractory AML Phase 2 results were scheduled for presentation at the ASH Annual Meeting, December 12–15, 2026.